Blood Thinners After TAVR: Antiplatelets, Anticoagulants, and How Long They Continue

After TAVR, most people go home on a single antiplatelet tablet, usually low dose aspirin, taken long term; lifelong warfarin is not needed because the new valve is made of tissue, and a stronger anticoagulant is only added when there is a separate reason for it, most often atrial fibrillation. That single sentence would have saved me a good deal of worry. The words “blood thinners” on my discharge sheet conjured up the warfarin clinic a friend from my choir had attended for years, the fortnightly blood tests, the lists of foods to avoid. What I actually went home with was much simpler, and the reasoning behind it, once someone explained it, made complete sense. This is that reasoning laid out plainly: which tablets are used, what each one is for, how long they carry on, and where the plan changes.

Why the tablets are needed at all

Any new valve presents a foreign surface to the blood, and blood, given a foreign surface, tends to clot on it; the tablets reduce that tendency while the valve’s frame and leaflets are covered over by the body’s own lining. A TAVR valve is a set of treated animal tissue leaflets mounted on a metal frame, expanded inside the old valve, as described in what TAVR is. Over the first months the frame becomes lined with the body’s own cells, after which the clotting risk from the device itself falls away ¹.

Two distinct things can go wrong in that window. A clot can form on the leaflets themselves, which at worst stiffens them and at the very least shows up as a worry on a scan. Or a clot can break free and travel to the brain, which is a stroke. Stroke around the time of TAVR runs at roughly 2 to 3 percent, and the tablets are one of several measures aimed at keeping that figure where it is ². The full picture of what can go wrong, and how often, is in the risks and complications of TAVR.

Antiplatelet or anticoagulant: two different jobs

An antiplatelet stops platelets, the tiny cell fragments that begin a clot, from sticking together on a surface; an anticoagulant works further down the chain, slowing the proteins that turn a cluster of platelets into a solid clot. Both get lumped together as blood thinners, and neither actually thins anything, but they suit different situations ³.

Antiplatelets, of which aspirin and clopidogrel are the common ones, are best at preventing the platelet-rich clots that form on artificial surfaces in fast-moving blood: the frame of a valve, the inside of a coronary stent. Anticoagulants, which include warfarin and the newer direct oral anticoagulants, are best at preventing the clots that form in slow-moving or pooled blood, which is what happens in the upper chambers of the heart during atrial fibrillation. That is the whole logic of the plan after TAVR: a valve on its own calls for an antiplatelet, and a valve plus atrial fibrillation calls for an anticoagulant ⁴.

The standard plan: one antiplatelet, long term

For someone with no other reason to be anticoagulated, both the European and the American guidelines settle on a single antiplatelet, usually aspirin, continued indefinitely after TAVR. The 2021 European guidance makes lifelong single antiplatelet therapy its clear recommendation, and the 2020 American guidance describes long term aspirin as reasonable in the absence of any other indication for anticoagulation ^{4 2}.

That is a lighter regime than most people expect. There are no blood tests to monitor it, no dietary restrictions, and the bleeding risk is far lower than with warfarin. The reason it is so light is that the valve is a bioprosthesis. Tissue valves do not require lifelong warfarin, unlike mechanical valves, which is the trade that decides so much in valve choice and which I set out in tissue versus mechanical and the TAVR designs.

Why two tablets were once routine, and often are not now

In the early years of TAVR, aspirin and clopidogrel together for the first 3 to 6 months was the standard, borrowed from coronary stenting; a large randomised trial then showed that the second tablet added bleeding without preventing strokes, and practice shifted towards aspirin alone. The American guidance still lists dual antiplatelet therapy for 3 to 6 months as something that may be reasonable, so you will meet both approaches depending on where and when you are treated ². The European guidance, written after that trial reported, comes down on the side of one tablet from the start ⁴.

I was treated in the middle of that shift. I went home with two boxes and a chart, took both for the first few months, and then, at a valve clinic, was told to drop to one. The nurse who told me said, with some feeling, that she was pleased to see the backs of the second box because of how many bruised and nose-bleeding patients it had produced over the years. Bleeding after TAVR is not trivial in people in their late seventies and eighties, which is most of us, and it is the reason the guidelines have moved in the direction of less rather than more ⁴.

When you already take an anticoagulant

Around a third of people having TAVR already have atrial fibrillation and take an anticoagulant for it; in that case the anticoagulant usually continues on its own after the procedure, and aspirin is not added on top. Both guidelines advise against routinely combining the two, because the extra bleeding outweighs any extra protection ^{2 4}.

What happens around the day itself varies by centre. Some teams pause the anticoagulant for a day or two before the procedure and restart it once the groin puncture is settled; others carry on through. Either way, the schedule is set for you and written down, and it is worth asking at the planning appointment exactly when to stop and when to restart, because that is the sort of instruction that gets lost between a busy ward and a taxi home. My neighbour, who had her valve done a year after me, was given the restart date verbally and spent an anxious weekend unsure whether she had heard it right. A written date is a fair thing to ask for.

Atrial fibrillation can also appear for the first time after TAVR, as a new irregular rhythm in the days after the procedure, and that is one of the reasons the heart’s rhythm is watched so closely on the ward. If it does, an anticoagulant may be started at that point rather than an antiplatelet, and the conduction problems that lead some people to a pacemaker, described in why some patients need a pacemaker after TAVR, are part of the same close watch on the heart’s electrics.

Leaflet thrombosis: the scan finding that worries people

A thin layer of clot on the new valve’s leaflets, sometimes with reduced leaflet movement, is seen on CT in roughly 10 to 15 percent of valves in imaging studies; most cases cause no symptoms and no harm, and routine anticoagulation to prevent it is not recommended. The finding, often written as leaflet thickening or reduced leaflet motion, was noticed once centres began scanning valves routinely, and it caused a stir because it was more common than anyone expected ⁵.

Two large trials then tested whether giving everyone an anticoagulant after TAVR would prevent it, and found that the anticoagulant caused more harm, through bleeding and other events, than the finding it was meant to prevent. The European guidance is explicit that anticoagulation is not recommended after TAVR in people who have no other reason for it ⁴. Where leaflet thrombosis is found and is affecting how the valve opens, a temporary course of an anticoagulant is sometimes used and the valve is rescanned; where it is found incidentally and the valve works normally, it is often simply watched. This is one of those areas where the plain summary is that the evidence is still maturing, and where the guidance is deliberately cautious about adding tablets.

How long it all goes on

The single antiplatelet is long term; a second antiplatelet, where used, stops after a set number of months; an anticoagulant for atrial fibrillation continues for as long as the atrial fibrillation does, which is usually for life. Those three timelines cover almost everyone. The one that changes most often is the middle one, and the change is made at a valve clinic rather than by the prescription quietly running out ⁶.

What you will be asked to do is simple and matters more than it sounds. Tell every dentist, surgeon and pharmacist that you have a prosthetic valve and what you take for it. Do not pause any of these tablets for a procedure without the heart team’s agreement; routine dental work usually goes ahead with a single antiplatelet continued, while larger procedures are planned around a pause and restart that the team sets ³. And report bleeding that is more than a nuisance, meaning black stools, blood in the urine, a nosebleed that will not stop, or bruising that arrives without any knock, because the dose and the choice of tablet can be adjusted once the team knows.

The tablets are only one strand of the longer routine that follows a valve procedure, alongside the yearly scan and the infection precautions, all of which are set out in living with a heart valve. I found that once I understood why each tablet was there, I stopped resenting the pill box on the kitchen windowsill. It is a small daily act of looking after something that, in my case, gave me back the hill to the shops.

---

General information, not medical advice. Which antiplatelet or anticoagulant you take, at what dose, and for how long, are decisions for your own cardiologist and heart team, who know your valve, your rhythm, and your bleeding history.